Vivo is expected to hold a major launch event in April in China. The event is likely to see the arrival of multiple devices, ...

Vivo is gearing up to launch its next big flagship, the X200 Ultra. Expected to launch in China sometime between mid-to-late ...

In fact, even some high-end smartphones fail to impress us when it comes to photography. Vivo is one of the few smartphone brands that has been challenging this notion, and with its latest vivo V50, ...

Truist analyst Joon Lee lowered the firm’s price target on Intellia Therapeutics (NTLA) to $50 from $90 and keeps a Buy rating on the shares.

Intellia Therapeutics’ stock faces risks from market uncertainty and funding needs. Read why NTLA stock is downgraded to HOLD ...

Intellia reports better-than-expected fourth-quarter 2024 results. The company provides updates on its pipeline candidates.

That same week, 16-year-old Nex Benedict woke up on the floor of their school bathroom after having their head repeatedly slammed into the tile, after having “blacked out” as they described hours ...

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Intellia's technology platform specializes in Clustered Regularly Interspaced Short ...

This transformative therapy would also be the first approved using in vivo CRISPR gene editing. Let's move on to nex-z in development for the treatment of ATTR amyloidosis. Starting with ATTR ...

Dosed first patient in global Phase 3 HAELO study evaluating NTLA-2002 for hereditary angioedema (HAE)Expect to complete enrollment of the HAELO ...